Supplemental material
Current Medical Research and Opinion
Volume 40, 2024 - Issue 2
Hematology
A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma
Isha Mola Cytel Inc., Rotterdam, The NetherlandsCorrespondence[email protected]
https://orcid.org/0009-0009-6366-9178
https://orcid.org/0009-0009-6366-9178, , Thomas W. LeBlancb Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC, USAhttps://orcid.org/0000-0002-0546-7895
https://orcid.org/0000-0002-0546-7895, , Haitao Chud Pfizer Inc., New York, NY, USAhttps://orcid.org/0000-0003-0932-598X
https://orcid.org/0000-0003-0932-598X, , , Alex Schepartd Pfizer Inc., New York, NY, USAhttps://orcid.org/0009-0000-3332-0180
https://orcid.org/0009-0000-3332-0180 & show all